SURVYR

NDRA

ENDRA Life Sciences Inc.
$4.62
+$0.16 (3.47%)Oct 21 close
Healthcare CompareTechnicals
-53%-36%-18%0%+17%Oct 2025Oct 2026Apr 202652w high $6.9552w low $2.96
NDRASPY
Wall St. Highest PT $25.00 (+440.5%) Wall St. Avg PT $25.00 (+440.5%)
$3$9$15$21$27POC $5Hi $25Avg $25
Underwater Drawdown %Max DD -51.3%Current -31.0%
0.0%-51.3%
Relative Strength vs SPY-43.2% vs SPYUnderperforming
+56%0%-56%
1W
−$0.15 (3.14%)
1M
−$1.68 (26.70%)
3M
−$0.99 (17.56%)
6M
−$0.78 (14.35%)
YTD
+$0.09 (2.10%)
1Y
−$1.51 (24.55%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Analyst price targets
Current price$4.62
Average target$25.00
+$20.38 (+440.5%) upsideaverage target vs current price
12-month Wall Street target range
Recent analyst rating changes · 7
Reiterated
2026-06-01 · Ascendiant Capital reiterated Buy on NDRA
Reiterated
2025-12-08 · Ascendiant Capital reiterated Buy on NDRA
Reiterated
2025-09-22 · Ascendiant Capital reiterated Buy on NDRA
Reiterated
2025-05-30 · Ascendiant Capital reiterated Buy on NDRA
Reiterated
2025-04-21 · Ascendiant Capital reiterated Buy on NDRA
Reiterated
2024-06-07 · Ascendiant Capital reiterated Buy on NDRA

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$6.9M
P/E (next 12 months, estimated)-1.5
52-week range$2.96 – $6.95
Dividend yieldNo dividend
Average analyst price target$25.00 (+441%)

What they do

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for NDRA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
Momentum Top 15
Outside this model's universe or screens
Momentum Blend
Not in the current book
New Highs Growth
Outside this model's universe or screens
SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
SURVYR. Long Book
Not in the current book

Earnings & events

NDRA earningsNo upcoming date on file
Last 4 quarters · EPS vs estimate
Aug 14, 2026-$1.17est -$0.84−39.4%Below estimates
May 15, 2026-$1.09est -$1.23+11.4%Above estimates
Mar 31, 2026-$2.23est -$1.23−81.7%Below estimates
Nov 14, 2025-$2.10est -$1.95−7.7%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 12:16:16 ET
24-1125-0325-0525-0825-1126-0326-0526-08-62.3025.20
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · Aug 17
Rating changes
Reiterated
2026-06-01 · Ascendiant Capital reiterated Buy on NDRA
Reiterated
2025-12-08 · Ascendiant Capital reiterated Buy on NDRA
Reiterated
2025-09-22 · Ascendiant Capital reiterated Buy on NDRA
Reiterated
2025-05-30 · Ascendiant Capital reiterated Buy on NDRA
Reiterated
2025-04-21 · Ascendiant Capital reiterated Buy on NDRA
Reiterated
2024-06-07 · Ascendiant Capital reiterated Buy on NDRA

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 12:16:16 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

Coteau 0.9 · Oct 21, 2026